quinazolines has been researched along with Lymphoma, Large B-Cell, Diffuse in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ardeshna, K; Beckmann, G; Buvaylo, V; Childs, BH; Chong, G; Gorbatchevsky, I; Haaber, J; Haioun, C; Hawkes, E; Hiemeyer, F; Lenz, G; Lippert, S; Peña, C; Piraino, P; Salles, G; Seog Heo, D; Shi, W; Thye Lim, S; Verhoef, G | 1 |
| Markham, A | 1 |
| Bu, W; Chang, G; Chang, S; Dai, B; Hou, J; Hu, L; Kong, Y; Lan, X; Shi, J; Tao, Y; Wang, Y; Wei, Q; Wu, H; Xiao, W; Xie, B; Xie, Y; Yang, G; Yu, D; Zheng, J | 1 |
| Hallek, M; Hassenrück, F; Krause, G | 1 |
| Bojarczuk, K; Chapuy, B; Chen, L; Lawton, LN; Letai, A; Mandato, E; Ryan, JA; Shipp, MA; Stachura, J; Villalobos-Ortiz, M; Wienand, K | 1 |
| Ashton, S; Barry, ST; Carnevalli, LS; Curtis, NJ; Ferguson, D; Floc'h, N; Harris, E; Hattersley, M; Hughes, AM; Maratea, K; Pease, EJ; Pilling, JE; Taylor, P; Wen, S; Young, LA | 1 |
| Collins, GP; Eyre, TA; Hatton, C; Linton, KM; Radford, J; Soilleux, E; Vallance, GD | 1 |
| Chen, L; Dörken, B; Enns, A; Lenz, G; Lenz, P; Loo, A; Naylor, TL; Ratsch, BA; Schuler, W; Stegmeier, F; Tang, H; Warmuth, M; Waters, NJ; Yao, YM | 1 |
2 review(s) available for quinazolines and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Copanlisib: First Global Approval.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines; Rituximab; United States; United States Food and Drug Administration | 2017 |
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Topics: Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones | 2018 |
2 trial(s) available for quinazolines and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; CD79 Antigens; Female; High-Throughput Nucleotide Sequencing; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2020 |
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome | 2015 |
4 other study(ies) available for quinazolines and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
Topics: Animals; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Gene Silencing; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oncogene Proteins; Protein Kinase C; Pyrroles; Quinazolines; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2018 |
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Topics: Acetanilides; Animals; Aurora Kinase B; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Nanoparticles; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2019 |
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Topics: Animals; CARD Signaling Adaptor Proteins; CD79 Antigens; Cell Growth Processes; Cell Line, Tumor; G1 Phase; Guanylate Cyclase; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mutation; NF-kappa B; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrroles; Quinazolines; Signal Transduction | 2011 |